A clinical case of successful treatment of a giant serous endometrial carcinoma imitating ovarian cancer
Open Access
- 15 December 2021
- journal article
- research article
- Published by ECO-Vector LLC in Journal of Clinical Practice
- Vol. 12 (4) , 80-85
Abstract
Background: Giant tumors of the abdominal cavity, as a rule, occur in elderly patients with characteristic features and represent a serious problem in terms of choosing a radical method of therapy. Of particular difficulty are cases of giant serous endometrial cancer, requiring a differential diagnosis with ovarian cancer. Clinical case description: A clinical case of giant serous endometrial cancer mimicking ovarian cancer in a 55-year-old woman is presented. The patient came to the oncology department with complaints of abdominal enlargement, difficulty breathing and bloody discharge from the genital tract. The examination revealed the following: a giant formation (4065 cm), occupying the entire pelvic and the entire abdominal cavities, ascites, lesions of the retroperitoneal lymph nodes, and the greater omentum, an umbilical hernia. A chest CT showed multiple contrast-accumulating circular shadows of 313 mm (metastases). By the decision of the council, after the preliminary chemoembolization of both the uterine and ovarian arteries, a supravaginal amputation of the uterus with appendages was performed, along with the resection of the greater omentum, removal of the umbilical hernia with positioning a plastic mesh implant and excision of an excess skin flap. The histological examination of the intraoperative material made it possible to verify the diagnosis of a serous endometrial carcinoma with subtotal tumor necrosis, the myometrium invasion of more than a half of its thickness, with the egress to the perimetrium, metastatic lesions of both ovaries, the greater omentum, anterior abdominal wall. Stage T3b (FIGO IIIB). In the postoperative period, 6 courses of Paclitaxel / Carboplatin (AUC4-5) chemotherapy were carried out with a pronounced clinical effect. The patient was discharged in a satisfactory condition. The control PET-CT scan after the 6th chemotherapy course showed no pathology in the thoracic cavity, and no process progress in the abdominal cavity. Currently, the remission of the disease is 9 months. Conclusion: An algorithm for the diagnostic measures aimed at making the correct diagnosis is presented, and the tactics of treating a patient with giant serous endometrial cancer is described.Keywords
This publication has 13 references indexed in Scilit:
- Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysisGynecologic Oncology, 2019
- Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neuJournal of Clinical Oncology, 2018
- Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease SettingsThe Oncologist, 2016
- Targeted Therapy in the Treatment of Uterine Serous CarcinomaPharmacogenomics, 2015
- The Emerging Genomic Landscape of Endometrial CancerClinical Chemistry, 2014
- Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53Gynecologic Oncology, 2013
- Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 2012
- EverolimusClinical Cancer Research, 2010
- Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancersBritish Journal of Cancer, 2006
- Adjuvant Radiotherapy in Endometrial CarcinomaThe Oncologist, 2005